NASDAQ:ARQT

Arcutis Biotherapeutics Stock Forecast, Price & News

$21.87

-0.11 (-0.50 %)

(As of 10/20/2021 02:18 PM ET)

Add

Compare

Today's Range

$21.62

▼

$22.01

50-Day Range

$19.28

▼

$25.50

52-Week Range

$17.51

▼

$38.49

Volume1,007 shs

Average Volume215,115 shs

Market Capitalization$1.10 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.15

30 days | 90 days | 365 days | Advanced Chart

Receive ARQT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5.1%
October 18, 2021 | americanbankingnews.com

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $21.97
October 13, 2021 | americanbankingnews.com

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) CEO Sells $62,300.00 in Stock
October 7, 2021 | americanbankingnews.com

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.9%
October 7, 2021 | americanbankingnews.com

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down to $25.50
October 6, 2021 | americanbankingnews.com

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
October 4, 2021 | finance.yahoo.com

Mizuho Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)
October 2, 2021 | americanbankingnews.com

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%
September 30, 2021 | americanbankingnews.com

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
September 30, 2021 | finance.yahoo.com

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
September 29, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARQT
Previous Symbol
CUSIP: N/A
CIK: 1787306
Web: www.arcutis.com
Phone: 805-418-5006
Employees: 54
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.20 per share
Price / Book: 3.53

Profitability

EPS (Most Recent Fiscal Year): ($3.80)
Net Income: $-135.68 million
Net Margins: N/A
Return on Equity: -45.92%
Return on Assets: -42.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 32.03
Quick Ratio: 32.03

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 50,242,000
Market Cap: $1.10 billion
Next Earnings Date: 11/4/2021 (Estimated)
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

2.41 out of 5 stars

Medical Sector

176th out of 1,360 stocks

Pharmaceutical Preparations Industry

75th out of 667 stocks

3.5 Analyst's Opinion

Consensus Rating
Arcutis Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.40, Arcutis Biotherapeutics has a forecasted upside of 149.7% from its current price of $21.79.
Amount of Analyst Coverage
Arcutis Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

4.4 Community Rank

Outperform Votes
Arcutis Biotherapeutics has received 23 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Arcutis Biotherapeutics has received 12 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Arcutis Biotherapeutics has received 65.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Arcutis Biotherapeutics and other stocks. Vote “Outperform” if you believe ARQT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARQT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Arcutis Biotherapeutics does not currently pay a dividend.
Dividend Growth
Arcutis Biotherapeutics does not have a long track record of dividend growth.

4.2 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $104,250.00 in company stock.
Percentage Held by Insiders
39.00% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.35% of the stock of Arcutis Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Arcutis Biotherapeutics are expected to decrease in the coming year, from ($4.38) to ($4.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcutis Biotherapeutics is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcutis Biotherapeutics is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcutis Biotherapeutics has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Arcutis Biotherapeutics (NASDAQ:ARQT) Frequently Asked Questions

Is Arcutis Biotherapeutics a buy right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcutis Biotherapeutics stock.
View analyst ratings for Arcutis Biotherapeutics or view top-rated stocks.
What stocks does MarketBeat like better than Arcutis Biotherapeutics?: Wall Street analysts have given Arcutis Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcutis Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
When is Arcutis Biotherapeutics' next earnings date?: Arcutis Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arcutis Biotherapeutics.
How were Arcutis Biotherapeutics' earnings last quarter?: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Thursday, August, 5th. The company reported ($0.84) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.94) by $0.10.
View Arcutis Biotherapeutics' earnings history.
How has Arcutis Biotherapeutics' stock been impacted by Coronavirus?: Arcutis Biotherapeutics' stock was trading at $25.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARQT stock has decreased by 12.9% and is now trading at $21.77.
View which stocks have been most impacted by COVID-19.
What price target have analysts set for ARQT?: 5 brokerages have issued 12-month price objectives for Arcutis Biotherapeutics' shares. Their forecasts range from $36.00 to $80.00. On average, they expect Arcutis Biotherapeutics' share price to reach $54.40 in the next year. This suggests a possible upside of 149.9% from the stock's current price.
View analysts' price targets for Arcutis Biotherapeutics or view top-rated stocks among Wall Street analysts.
Who are Arcutis Biotherapeutics' key executives?: Arcutis Biotherapeutics' management team includes the following people:
Mr. Todd Franklin Watanabe, Pres, CEO & Director (Age 53, Pay $734.63k) (LinkedIn Profile)
Dr. Bhaskar Chaudhuri, Co-Founder & Independent Director (Age 66, Pay $50.42k) (LinkedIn Profile)
Mr. Kenneth A. Lock, Chief Commercial Officer (Age 47, Pay $514.28k)
Dr. Patrick E. Burnett M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 49, Pay $619.79k)
Mr. Scott L. Burrows, CFO & Principal Accounting Officer (Age 44)
Ms. Patricia A. Turney, Sr. VP of Operations (Age 54)
Dr. David W. Osborne, Chief Technical Officer (Age 60)
Mr. Rajvir Madan, Chief Digital & Information Officer
Mr. Keith L. Klein, Gen. Counsel & Sec. (Age 57)
Ms. Courtney Barton, Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer (Age 38)
Who are some of Arcutis Biotherapeutics' key competitors?: Some companies that are related to Arcutis Biotherapeutics include Arvinas (ARVN), 23andMe (ME), Schrödinger (SDGR), Karuna Therapeutics (KRTX), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Zentalis Pharmaceuticals (ZNTL), Cryoport (CYRX), Intra-Cellular Therapies (ITCI), Galapagos (GLPG), Lyell Immunopharma (LYEL), Hypera (HYPMY), Cytokinetics (CYTK), Insmed (INSM) and Nektar Therapeutics (NKTR).
View all of ARQT's competitors.
What other stocks do shareholders of Arcutis Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).
When did Arcutis Biotherapeutics IPO?: (ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.
What is Arcutis Biotherapeutics' stock symbol?: Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."
Who are Arcutis Biotherapeutics' major shareholders?: Arcutis Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hamilton Lane Advisors LLC (0.10%). Company insiders that own Arcutis Biotherapeutics stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Jonathan Silverstein, Life Sciences Viii L Frazier and Todd Franklin Watanabe.
View institutional ownership trends for Arcutis Biotherapeutics.
Which institutional investors are selling Arcutis Biotherapeutics stock?: ARQT stock was sold by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC. Company insiders that have sold Arcutis Biotherapeutics company stock in the last year include Bhaskar Chaudhuri, Howard G Welgus, John W Smither, and Todd Franklin Watanabe.
View insider buying and selling activity for Arcutis Biotherapeutics or view top insider-selling stocks.
How do I buy shares of Arcutis Biotherapeutics?: Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arcutis Biotherapeutics' stock price today?: One share of ARQT stock can currently be purchased for approximately $21.77.
How much money does Arcutis Biotherapeutics make?: Arcutis Biotherapeutics has a market capitalization of $1.09 billion. The company earns $-135.68 million in net income (profit) each year or ($3.80) on an earnings per share basis.
How many employees does Arcutis Biotherapeutics have?: Arcutis Biotherapeutics employs 54 workers across the globe.
What is Arcutis Biotherapeutics' official website?: The official website for Arcutis Biotherapeutics is www.arcutis.com.
Where are Arcutis Biotherapeutics' headquarters?: Arcutis Biotherapeutics is headquartered at 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361.
How can I contact Arcutis Biotherapeutics?: Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected].

This page was last updated on 10/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Arcutis Biotherapeutics Stock Forecast, Price & News

About Arcutis Biotherapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

4.4 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

4.2 Company Ownership

0.0 Earnings and Valuation

Arcutis Biotherapeutics (NASDAQ:ARQT) Frequently Asked Questions

Is Arcutis Biotherapeutics a buy right now?

What stocks does MarketBeat like better than Arcutis Biotherapeutics?

When is Arcutis Biotherapeutics' next earnings date?

How were Arcutis Biotherapeutics' earnings last quarter?

How has Arcutis Biotherapeutics' stock been impacted by Coronavirus?

What price target have analysts set for ARQT?

Who are Arcutis Biotherapeutics' key executives?

Who are some of Arcutis Biotherapeutics' key competitors?

What other stocks do shareholders of Arcutis Biotherapeutics own?

When did Arcutis Biotherapeutics IPO?

What is Arcutis Biotherapeutics' stock symbol?

Who are Arcutis Biotherapeutics' major shareholders?

Which institutional investors are selling Arcutis Biotherapeutics stock?

How do I buy shares of Arcutis Biotherapeutics?

What is Arcutis Biotherapeutics' stock price today?

How much money does Arcutis Biotherapeutics make?

How many employees does Arcutis Biotherapeutics have?

What is Arcutis Biotherapeutics' official website?

Where are Arcutis Biotherapeutics' headquarters?

How can I contact Arcutis Biotherapeutics?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™